Thank you for Subscribing to Life Science Review Weekly Brief
Anifera is set to conduct additional research to investigate the impact and efficiency of adjunct therapy in bovine mastitis.
FREMONT, CA: Anifera, an organization dedicated to developing adjunct therapy to enhance the efficacy of antibiotics used in animal health, will be conducting additional research to investigate the impact and efficiency of adjunct therapy in bovine mastitis, a crucial economic and animal welfare concern for dairy farmers worldwide. The study will expand on promising initial data in bovine mastitis, and it comes after a considerable investment in the company by Stonehaven Incubate, a prominent investor in emerging, advanced animal health firms and a co-founder of Anifera.
Anifera is working on compounds that will enhance antibiotic effectiveness to minimize its use in animals. Through a novel mechanism of action, Aniferas small molecule compounds focus on strengthening the antibiotic's effects.
Dr Gwynneth Thomas, CEO of Anifera, commented: "We have seen very encouraging results in early studies focused on bovine mastitis, utilizing our lead compound as an adjunct therapy to a commercial intramammary antibiotic. We look forward to moving ahead with additional development work aimed at further exploring improvements in the efficacy of existing antibiotics when used in combination with our compound, helping to advance sustainability in animal health.
We are grateful for the continued commitment of Stonehaven Incubate as we seek to bring these potentially ground-breaking compounds to market as soon as possible."
Dr Simon Wheeler, a member of the Aniferas Board, said: "Bovine mastitis is a huge economic challenge for the dairy industry, affecting the yield and quality of milk and impacting animal welfare. With increasing concerns and restrictions on the use of antibiotics in farm animals, Aniferas innovative approach could help improve health and productivity for dairy farmers worldwide."
JarneElleholm, CEO of Stonehaven Incubate, added: "Anifera has the potential to pioneer new ways of treating bovine mastitis, offering immediate financial and welfare benefits to dairy farmers. We are committed to helping Anifera advance these important studies and drive innovation to improve the efficacy of antibiotics. We share their goal of ultimately reducing the usage of antibiotics in disease states across animal health where they are the first line of treatment."